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Background: Treatment protocols for nasopharyngeal carcinoma (NPC) developed in the past decade have
significantly improved patient survival. In most NPC patients, however, the disease is diagnosed at late stages, and
for some patients treatment response is less than optimal. This investigation has two aims: to identify a
blood-based gene-expression signature that differentiates NPC from other medical conditions and from controls
and to identify a biomarker signature that correlates with NPC treatment response.
Methods: RNA was isolated from peripheral whole blood samples (2 x 10 ml) collected from NPC patients/controls
(EDTA vacutainer). Gene expression patterns from 99 samples (66 NPC; 33 controls) were assessed using the
Affymetrix array. We also collected expression data from 447 patients with other cancers (201 patients) and
non-cancer conditions (246 patients). Multivariate logistic regression analysis was used to obtain biomarker
signatures differentiating NPC samples from controls and other diseases. Differences were also analysed within a
subset (n = 28) of a pre-intervention case cohort of patients whom we followed post-treatment.
Results: A blood-based gene expression signature composed of three genes — LDLRAP1, PHF20, and LUC7L3 — is
able to differentiate NPC from various other diseases and from unaffected controls with significant accuracy (area
under the receiver operating characteristic curve of over 090). By subdividing our NPC cohort according to the
degree of patient response to treatment we have been able to identify a blood gene signature that may be able to
guide the selection of treatment.
Conclusion: We have identified a blood-based gene signature that accurately distinguished NPC patients from
controls and from patients with other diseases. The genes in the signature, LDLRAP1, PHF20, and LUC7L3, are
known to be involved in carcinoma of the head and neck, tumour-associated antigens, and/or cellular signalling.
We have also identified blood-based biomarkers that are (potentially) able to predict those patients who are
more likely to respond to treatment for NPC. These findings have significant clinical implications for optimizing
NPC therapy.
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Nasopharyngeal carcinoma (NPC) is a squamous cell
carcinoma arising in the nasopharyngeal epithelial lining,
where the back of the nose meets the throat. The cancer
is rare in most parts of the world, with an incidence of
less than one per 100,000 populations in Europe and* Correspondence: cliew@genenews.com
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NPC is much more common. The highest incidence
worldwide occurs in southeast China; in Hong Kong for
example, NPC affects approximately 20–30 per 100,000
men and 15–20 per 100,000 women [1]. In Malaysia,
NPC is the third most common cancer in men (after
colon cancer and lung cancer), with an incidence of 159
per 100,000 in Chinese males in Malaysia [2].
The disease is more often diagnosed in men than in
women, and tends to occur at an earlier age than do
most cancers. In high-risk populations the risk of NPCtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cidence at 45–54 years. In moderate-risk groups, such as
populations in North Africa, there is an additional peak
in adolescence and youth (ages 10–20) [3].
NPC seems to involve a combination of etiological fac-
tors, both genetic and environmental [3,4]. The disease
is strongly linked to Epstein-Barr virus (EBV), a herpes-
virus transmitted by saliva and carried by 90% of the
population. EBV is detected in plasma of 95% of patients
with pre-malignant NPC lesions/tumour cells, and ser-
ology screening has been used for NPC screening in en-
demic areas [5,6].
The symptoms of NPC are non-specific, including
neck mass, nasal and aural dysfunction and headaches,
and clinical examination of the nasopharynx is difficult.
Thus, more than 60% of patients with NPC present at
locally advanced stages III and IV.
The awkward location of the nasopharynx also means
that surgery is uncommon in NPC. Standard treatment
of locoregional advanced NPC involves radiation therapy
alone for earlier stages I and II cancer and radiation and
concurrent cisplatin-based chemotherapy for later stages
of the disease. Patients with stage I and II disease can
usually be treated with radiotherapy alone, with excellent
survival rates of 80–95% [7]. With chemoradiotherapy,
patients with stage III and IV disease have reported 3-
year survival rates of 70–80% [8,9]. In patients with re-
current or metastatic disease the prognosis is poor, with
a median survival time of less than one year [7]. Un-
desirable complications of chemoradiotherapy for NPC
can be severe and can limit patient compliance [8]. A
blood test that could identify pre-symptomatic, earlier-
stage NPC would help to increase patient survival and
reduce treatment-related toxicity; a blood test that could
predict patient response to therapy could increase com-
pliance with treatment regimens.
In this report, we used blood samples to identify gene
expression signatures for NPC and to predict patient re-
sponse to treatment. Such a test would significantly im-
prove the medical management of this disease.Methods
Patients and blood samples
Blood samples were collected from patients with NPC
recruited at Mount Miriam Cancer Hospital (Penang,
Malaysia). Consent forms were obtained from all study
participants according to protocols approved by the hos-
pital’s Research Ethics Board.
We performed gene profiling and microarray analysis
on 66 samples taken from patients with tumours con-
firmed as NPC by hospital pathologists, and for 33 con-
trols (Table 1), collected between November 2006 and
April 2010.To obtain a gene signature specific to NPC, we
included 447 expression profiles of samples with other
conditions (27 bladder cancer; 10 breast cancer; 17 cer-
vical cancer; 16 endometrical cancer; 40 ovarian cancer;
91 prostate cancer; 47 Crohn’s disease; 43 osteoarthritis;
38 rheumatoid arthritis; 85 cardiovascular disease; 20
schizophrenia; 13 miscellaneous other conditions).
Blood collection, RNA isolation and RNA quality control
Peripheral whole blood (2x10 ml) was collected from
patients in EDTA Vacutainer tubes (Becton Dickinson,
New Jersey, USA), and RNA was isolated as described
previously [10]. Isolated RNA was checked using 2100
Bioanalyzer RNA 6000 Nano Chip (Agilent Technolo-
gies, California, USA). Samples were excluded for subse-
quent microarray analysis that did not meet the following
quality criteria: RIN>= 70; 28S:18S rRNA>=10. RNA
quantity was determined by absorbance at 260 nm in a
DU640 Spectrophotometer (Beckman-Coulter, California,
USA).
Microarray hybridization
Five micrograms of RNA from each sample were used
for cDNA synthesis and hybridization, following the
standard Affymetrix protocol (Affymetrix GeneChip,
HG-U133 Plus 20). Hybridizations were assessed by the
quality threshold for the Affymetrix GeneChip suggested
by the manufacturer.
Microarray analysis of NPC vs. controls and other diseases
Details of the statistical analysis are described in the
Additional file 1.
Microarray analysis of complete response to treatment
(CR) vs partial response (PR) to treatment
Follow-up information from clinicians was available for
28 of the NPC cases. All but one of the patients had
been treated with standard radiotherapy and 5–7 weeks
cisplatin-based therapy (one patient received only radio-
therapy), and the patients were followed for between
one and three years. Clinical information for the cohort
is presented in Table 2.
As evaluated with computed tomography scans taken at
the last visit, 15 cases were classified as complete response
to treatment (CR), that is, no evidence of disease was
present, and 13 were classified as partial response to treat-
ment (PR), that is, residual disease or metastasis was
present. Gene profiles were analysed to identify a suite of
biomarker genes capable of predicting a patient’s response
to treatment. (Analysis is described in the Additional file 1.)
Pathway analysis
Pathway analysis was performed using GeneSpring GX
(version 10). BioPAX format pathways were imported
Table 1 Clinical characteristics of the patient cohorts for microarray hybridization
Characteristics NPC Control P value* Control & 447 Other P value*
(NPC vs Control) (NPC vs Control & 447 Other)
No. 66 33 480
Age - Median (Range) 51 (24–74) 31 (19–74) <001 55 (19–86) 0.32
Ethnicity - no. (%)
Malay 12 (182) 2 (61) 013 n/a n/a
Chinese 45 (682) 30 (909) 001 n/a n/a
Indonesian 8 (121) 0 (00) 005 n/a n/a
Indian 0 (00) 1 (30) 033 n/a n/a
Unknown 1 (15) 0 (00) 100 n/a n/a
Sex
Male 49 (742) 20 (606) 017 242 (57.1) 0.01
Female 17 (258) 13 (394) 017 182 (42.9) 0.01
not available 56
* P values for age and BMI were calculated using the Mann–Whitney test, P values for ethnicity, sex and medical conditions were calculated using Fisher’s
exact test.
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Similar Pathway Tool” was used to identify pathways
with considerable enrichment of the genes from our
study. P-values were calculated using hypergeometric
distribution or the Fisher’s exact test; the cut-off was set
at < 005.
Results
Of the 66 patients with NPC, there were more males
than females (49 males, 17 females; see Table 1), a find-
ing consistent with previous studies indicating that the
incidence of NPC is higher in men than in women
(male: female ratio = 3:1). We selected 66 samples for
this study (36 newly diagnosed NPC (pre-treatment) and
30 post-treatment samples). Patient age, gender and
other variables are shown in Table 1. To obtain genome-
wide expression data for the samples, 66 hybridizations
using Affymetrix GeneChip were performed.
NPC gene signature identification
Microarray hybridizations were carried out to generate
gene expression profiles for 66 blood samples from NPC
patients, irrespective of treatment stage, and 33 control
samples from Mount Miriam Cancer Hospital. Data ana-
lysis flow of the microarray data is shown in Figure 1
and in the Additional file 1. Using multivariate logistic
regression analysis, we first selected 121 combinations of
six probe sets with an AUC greater than 090 that separ-
ate NPC samples from unaffected controls and from
patients with other diseases. The 121 combinations of
six probe sets comprised 234 unique probe sets.
Of the 234 probe sets, we found that the three selected
most frequently and in the best combinations mapped to
genes LDLRAP1 (low density lipoprotein receptor
adaptor protein 1), PHF20 (PHD finger protein 20) andLUC7L3 (cisplatin resistant-associated overexpressed
protein, also known as CROP), with AUCs of 092, 097
and 096, respectively (Figure 2). The standard errors
were relatively very small, at 0013, 0007 and 0008, re-
spectively. The cluster diagram in Figure 2 is based on a
combination of these three primary genes with 3 second-
ary suppressor genes and shows that, to a large extent,
the NPC samples stand apart from the controls, which
are dispersed throughout the group of samples with
other diseases.
This combination of three primary genes (LDLRAP1,
PHF20, LUC7L3), together with their associated sup-
pressor genes (EZH1, IFI35, UQCRH), was subjected to
2-fold cross-validation with 1000 iterations. The average
ROC AUC was 0.98 (95% C.I. 0.98 – 0.99). An equiva-
lent analysis using randomized NPC status achieved an
average ROC AUC of 0.50 (95% C.I. 0.37 – 0.62). There
was no overlap between these two distributions.
These 6 genes were run on qPCR for a subset of 26
controls and 44 NPC cases for which sufficient mRNA
was available. The three gene pairs qPCR data confirmed
the fold change directions observed in the microarray
data with two of the three pairs remaining statistically
significant (p-value < 0.01). The 3-pair combination
maintained a high level of discrimination between cancer
and controls with a 95% confidence interval (CI) for the
ROC AUC of 0.75 to 0.93, overlapping that of the micro-
array data (95% CI: 0.91 to 1.00).Expression pattern difference reflecting
treatment response
We subdivided a cohort of NPC patients prior to treat-
ment (n = 28), according to the degree of patient re-
sponse to treatment at one to three years of post-
Table 2 Pathology information for the 28 samples
Case PR/CR Tumour type TNM Staging
1 PR Undifferentiated squamous cell carcinoma T3NxMx
2 PR Undifferentiated cell carcinoma WHO type III T3N3Mx
3 PR Moderately differentiated squamous cell carcinoma T3N3Mx
4 PR Undifferentiated Carcinoma T3N3Mx
5 PR Infiltrating, non-keratinising undifferentiated carcinoma;
Loc adv NPC T1-2N2Mx with neck node mets, residual lesion
T3N3Mx
6 PR Undifferentiated carcinoma ; CA nasopharynx stage III T3N1Mx
7 PR Moderately differentiated squamous cell carcinoma, keratinizing,
NPC with Extensive right neck node mets; Residual disease and
neck node; stable disease liver lesion
T2N3Mx
8 PR Undifferentiated carcinoma WHO-3 , infiltrating T2N1Mx
9 PR Undifferentiated carcinoma WHO - 3, infiltrating; Loc adv NPC with
neck node mets and multiple cranial nerces invol
T4N3Mx
10 PR Undifferentiated carcinoma T2N3Mx
11 PR Poorly differentiated carcinoma T2N?Mx
12 PR Infiltrating, non-keratinizing undifferentiating carcinoma WHO type III tumour T2N1Mx
13 PR Poorly differentiated or anaplastic carcinoma T2N1Mx
14 CR Invasive, non-keratinising undifferentiated carcinoma WHO type III tumour T3N2Mx
15 CR Undifferentiated carcinoma, infiltrating; carcinoma of the nasopharynx,
tumour involving the sphenoid bone & extending into the sphenoid sinus.
T4N2Mx
16 CR Undifferentiated carcinoma T2N2Mx
17 CR Undifferentiated carcinoma, infiltrating, non-keratinizing WHO type III;
Undiff NPC with retropharyngeal and left internal post jugular lymphadenopathy,
for restaging.
T3N3Mx
18 CR Undifferentiated carcinoma; Loc adv NPC T3N0Mx extending to the left
parapharyngeal region
T3N0Mx
19 CR Undifferentiated carcinoma T4N1Mx
20 CR Undifferentiated carcinoma T3N1Mx
21 CR Undifferentiated carcinoma (with left vocal cord palsy) T3N2Mx
22 CR Undifferentiated carcinoma (with cervical node metastases); NPC with neck node mets T3N2Mx
23 CR Undifferentiated carcinoma T3N2Mx
24 CR Non-keratinizing undifferentiated carcinoma, WHO type III, restaging T2N1Mx
25 CR Undifferentiated carcinoma; CT scan - neck node T2N1Mx
26 CR Undifferentiated carcinoma; Loc adv carcinoma of the nasopharynx with neck node
mets, extension to parapharyngeal region right more than left and involvement of the
ptergoid muscles
T3N2Mx
27 CR Infiltrating non keratinising undifferentiated carcinoma; Tumour involv. Both FOR with
parapharyngeal & rectopharyngeal extension
T3N1Mx
28 CR Undifferentiated carcinoma; loc adv T4N1Mx. Tumour involv PNS, clivus, paratracheal &
prevertebral muscles, ant nasal cavity and ext to both middle cranial fossa (extradural mass)
T4N1Mx
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pairs with ROC AUC ranging up to 094.
There were only 78 unique genes in the top
50-performing six-gene combinations, an enrichment
factor of more than 3. This suggests that these genes
are essential combination pairs and should have im-
portant biological roles in differentiating CR and PR.
To elucidate such roles, we analyzed the 78 genes for
their known involvement in relevant biological path-
ways. We found that three of the genes are involved
in the 135-gene B-cell antigen receptor (BCR) pathway(p-val = 1.12E-04) and five genes are involved in the
176-gene epidermal growth factor receptor (EGFR)
pathways (p-val = 0.024).
The four genes appearing most frequently in the com-
bination were: forkhead box P1 (FOXP1, 34 combina-
tions); egf-like module containing, mucin-like hormone
receptor-like 2 (EMR2, 26 combinations); syntaxin 16
(STX16, 12 combinations); and N-acetylglucosamine-1-
phosphate transferase (GNPTAB, 12 combinations). The
best pair combination from these 4 genes with ROC
AUC=0.89, was FOXP1 and STX16 (Figure 3).
Figure 1 Data Analysis Outline. (a) Microarray gene profiling raw data were pre-processed for quality control before analysis. First, all samples
were normalized using MAS5 algorithm and only probes flagged as “present” were retained. The “present” probes were then compared with the
list generated in MAQC studies for Affymetrix Human U133 plus 2; non-overlapped probes were deemed unreliable and, therefore, excluded.
Expression values of each probe were then logarithm transformed. (b) Logistic regression multivariate analysis of the gene expression values was
performed to evaluate the AUC of each gene and of different multi-gene combinations. Significance of associations between gene expressions
was determined using a logrank test. The best set of coefficient values that maximize the separation between the positive and negative groups
were determined. Later, the log ratio calculation was determined in order to reduce the impact of possible noise (c). Thresholds were then set to
evaluate sensitivity, specificity and the stability of the prediction. Two individual genes were combined to form a gene pair (d). Then the single
pair of genes was coupled to form 2-pair and then 3-pair gene combinations. Logistic regression values were calculated for each gene pair, and
we showed that in each case when genes were combined, the area under the curve (AUC ROC) increased.
Figure 2 ROCs of probes that contribute to differentiation of nasopharyngeal carcinoma from other conditions. Combination of 6 genes
with three genes appearing most frequently in all top-performing combinations LDLRAP1, PHF20 and LUC7L3. The additional three secondary
genes have little NPC discrimination (ROC AUC: 0.51 – 0.77) but help suppress confounding factors. ROC AUC for each gene is listed in table.
Dendrogram for the six-gene combination showing control samples dispersed throughout the “other” sample group with a separate cluster
consisting mainly of NPC samples on the right. Heat map and clustering are based on results of 2-fold cross validation iterated 1000 times.
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Box-and-Whisker Plot
(Error Bars: 95% CI for Median)
Figure 3 Box-and-whisker median plot, hierarchical clustering results and ROC of Complete Response (CR) and Partial Response (PR)
samples. The box-and-whisker median (error bars: 95% CI for medians) plot for distribution of Complete Response (CR) and Partial Response (PR)
for pair FOXP1 and STX16, showing good differentiation between the groups. The dendrogram represents the hierarchical clustering results of
pre-intervention NPC samples. The coloured boxes directly below the dendrogram represent samples that show complete response (CR) to
treatment and partial response (PR) to treatment, denoted in green and red, respectively. We found two major clusters in the samples; the cluster
on the right consists of 8 of 13 (62%) PR samples (red) and the cluster on the left consists of 14 of 15 (93%) CR samples (green). Dot plot, heat
map and clustering are based on results of 3-fold cross validation iterated 1000 times. The AUC for the single pair equation is 089, with a
standard error of 0067.
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the remainder of the analysis to this single pair of genes.
We subjected the pair combination of FOXP1 and
STX16 to cross validation analysis using 3-fold partition-
ing and iterated 1000 times. The average ROC AUC was
maintained at 0.89 (95% C.I. range of 0.84 to 0.94). A
“Null Set” analysis based on 1000 re-samplings of the
data set with randomized labels produced a ROC AUC
average of 0.50 (95% C.I. range of 0.29 to 0.71). There
was a less than 1% overlap between the distribution of
the cross validation using the actual data set and the
“null set”.
Discussion
The blood transcriptome is proving to be a valuable re-
source for biomarker identification and pharmacogen-
omics. In several studies we have shown that gene
signatures obtained using blood mRNA can identify a
variety of conditions including heart failure [11], cancer
[10,12,13], inflammatory bowel disease [14,15], and psy-
chiatric disorders [16-18]. In this study we have applied
our methodology, using whole blood samples from NPCpatients to compare gene expression patterns of NPC
with unaffected controls and with other conditions and
to compare blood gene expression patterns in NPC be-
fore and after radiotherapy and/or chemotherapy. Past
research has identified tissue-based biomarkers for pa-
tient survival in NPC [19]. This will be the first study to
develop a blood transcriptomic pharmacogenomic ap-
proach to guide treatment for NPC.
At the molecular level, LDLRAP1, PHF20 and
LUC7L3 were the three probe sets most frequently
selected for NPC discrimination. These genes have bio-
logical significance in NPC, as they are known to be
involved in carcinomas of the head and neck, tumour-
associated antigens, and/or cellular signalling. [20-26].
These results could throw light on biological pathways
involved in patient response to NPC treatment. LUC7L3
[cisplatin resistant overexpressed protein (CROP)] is
involved in RNA splicing or mRNA processing activities.
Its expression is higher in cisplatin resistant cell-lines
than in non-resistant cell-lines [23]. Cisplatin is believed
to affect the sub-nuclear distribution of the protein,
thereby interfering in RNA splicing and in the mRNA
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LUC7L3 was found to be significantly lower in NPC
samples than in controls and other cancer samples.
Cisplatin is widely used to treat NPC patients. However
primary and secondary cisplatin resistance is a major
limitation to the use of this drug in cancer chemother-
apy. Improved understanding of the mechanisms lead-
ing to cisplatin resistance may suggest molecular targets
for therapeutic intervention and may facilitate predic-
tion of response to therapy and individually tailored
therapy [25].
Biological function analysis also indicates a significant
enrichment of candidate genes involved in the BCR and
EGFR1 pathways. The BCR pathway responds to specific
antigens and is important for antibody production and
immune responses [27]. Changes in expression of genes
in this pathway may cause alterations in signal transmis-
sion within the cell, which can result in changes in
B-cell production, cell growth and cell division. EBV, a
herpesvirus strongly linked to NPC, replicates in B cells
and epithelial cells and reportedly contributes to tumori-
genesis [25]. Our finding of gene expression pathways in
the BCR pathway in NPC could improve our under-
standing of NPC treatment responses, as changes in
BCR pathways could lead to changes in EBV replication
and tumour formation.
The results of this study have two major clinical impli-
cations. First, although the majority of newly diagnosed
cases (75%) presented at late cancer stages, it is possible
that the signature identified here may also indicate the
presence of cancer at pre-symptomatic, earlier stages.
This could lead to the development of a blood test for
diagnosis at a stage at which the disease can be treated
with less toxicity and higher chances of long-term pa-
tient survival.
The second important objective of the study was to
determine whether expression information obtained
from the blood of NPC patients can be used to further
define appropriate treatment for individuals. In this con-
text, the challenge was to detect any subtle differences
evident in pre-intervention peripheral blood samples for
NPC patients whose treatment response has been moni-
tored for a period of time.Conclusion
In this study, NPC patients were diagnosed at later stage
III and IV cancer (the stage at which most NPC patients
are currently diagnosed). Whether the signature we have
identified can also be detected in patients at an earlier,
more treatable stage of the disease is an intriguing ques-
tion for future research. A signature for early stage can-
cer could form the basis of a clinically useful blood test
for the early diagnosis and screening of NPC.Our blood-based gene expression signature also identi-
fies those patients who are more likely to experience
complete response to current radiation and chemother-
apy regimens and those who can expect only a partial
response to therapy. A test to identify complete respon-
ders could encourage patient compliance in the presence
of treatment side-effects. Partial responders could be
considered for assignment to new treatment plans or
novel agents.
Additional file
Additional file 1: Statistical analysis for NPC and treatment
response discrimination.
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